Diagnostic Utility of Proliferative Cell Markers in Prostatic Lesions: An Institutional Experience

  • Vartika Goel Department of Pathology, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak (Haryana), India
  • Veena Gupta Department of Pathology, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak (Haryana), India
  • Nisha Marwah Department of Pathology, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak (Haryana), India
  • Niti Dalal Senior Resident, Department of Pathology
  • Promil Jain Department of Pathology, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak (Haryana), India
  • Rajeev Sen Department of Pathology, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak (Haryana), India
Keywords: Benign prostatic hyperplasia, Ki-67, Proliferating Cell Nuclear Antigen, Prostate carcinoma


Background: Prostatic cancer is a complex and biologically heterogenous disease. Diagnosis of prostatic lesions with immunohistochemistry still faces challenges because of difference in reactivity of monoclonal antibodies in benign, equivocal, and malignant lesions. Proliferative markers Ki-67 and Proliferating Cell Nuclear Antigen (PCNA) can be used for diagnosis and prognostic stratification of prostatic carcinoma. Methods: A total of hundred prostate biopsies with 50 cases each of benign prostatic hyperplasia and prostate carcinoma received in the Department of Pathology, PGIMS, Rohtak, India were included in the study. Ki-67 and PCNA expression was studied immunohistochemically in each case. Result: Ki-67 expression was significantly upregulated in malignant cases and increased with increasing Gleason grade. PCNA expression was also found to be increased in increasing Gleason grades in carcinoma cases, however, the results were ambiguous as it was found to be positive in all benign cases also. Conclusion: Ki-67 is useful in predicting biological behavior in prostate carcinoma cases, however PCNA expression needs to be studied further.


Miah S, Catto J. BPH and prostate cancer risk. Indian J Urol. 2014;30(2):214-8.

Manna AK, Pathak S, Gayen P, Sarkar DK, Kundu AK. Study of immunohistochemistry in prostatic lesions with special reference to proliferation and invasiveness. Indian J Surg. 2011;73(2):101-6.

Zhong W, Peng J, Wu D, Han Z, Bi X, Dai Q. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med. 2008;31(1):8-15.

Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol. 1996; 178:437-41.

Verma R, Gupta V, Singh J, Verma M, Gupta G, Gupta S, et al. Significance of p53 and ki-67 expression in prostate cancer. Urol Ann. 2015;7(4):488-93.

Kaur H, Paul M, Manjari M, Sharma S, Bhasin TS, Mannan R. Ki-67 and p53 immunohistochemical expression in prostate carcinoma: An experience from a tertiary care centre of North India. APALM. 2016;3(6): A509-16.

Mohamed AA, Abbas MY, Alharbi H, Babiker AY. Assessment of Expression of Ki-67 in Benign and Malignant Prostatic Lesions among Sudanese Patients. Open Access Maced J Med Sci. 2018;6(10):1809-12.

Wang X, Hickey RJ, Malkas LH, Koch MO, Li L, Zhang S, et al. Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. Prostate. 2011;71(7):748-54.

Montironi R, Mazzuccheli R, Scarpelli M, Lopez‐Beltran A, Fellegara G, Algaba F. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance, and sources of pathology discrepancies. BJU Int. 2005;95(8):1146-52.

Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: A validated alternative to the Gleason score. Eur Urol. 2016; 69(3):428– 35.

Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC. Expression of Bcl‐2, Bax, and p53 in high‐grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate. 1998;37(4):223-9.

Zeymer U, Fishbein MC, Forrester JS, Cercek B. Proliferating cell nuclear antigen immunohistochemistry in rat aorta after balloon denudation. Comparison with thymidine and bromodeoxyuridine labeling. Am J Pathol. 1992;141(3):685-90.

Cappello F, Rappa F, David S, Anzalone RI, Zummo G. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis. Anticancer Res. 2003;23(2B):1325-31.

Uemura H, Hoshino K, Sasaki T, Miyoshi Y, Ishiguro H, Inayama Y, et al. Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens. BJU Int. 2009;103(9):1190-4.

Munoz E, Gomez F, Paz JI, Casado I. Ki-67 immunolabeling in pre-malignant lesions and carcinoma of the prostate. Histological correlation and prognostic evaluation. Eur J Histochem. 2003;47(2):123-8.

Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Tenta R, et al. p27 kip1 and Ki-67 (MIB1) Immunohistochemical Expression in Radical Prostatectomy Specimens of Patients with Clinically Localized Prostate Cancer. In Vivo. 2005;19(5):911-20.

Zhong X, Lin J, Zhou J, Xu W, Hong Z, Peng J. Qianliening capsule treats benign prostatic hyperplasia (BPH) by downregulating the expression of PCNA, CyclinD1 and CDK4. Afr J Biotechnol. 2012;11(30):7731-7.

Shiraishi K. Proliferating Cell Nuclear Antigen (PCNA) in Prostatic Carcinoma. Acta medica Nagasakiensia. 1993; 38:74-8.

Miyamoto S, Ito K, Kurokawa K, Suzuki K, Suzuki K, Yamanaka H. Clinical validity of proliferating cell nuclear antigen as an objective marker for evaluating biologic features in patients with untreated prostate cancer. Int J Urol. 2006; 13:767-72.

Original Article